Get the Stockscreener App
1.34
8.84%
-0.13
After Hours:
1.35
0.01
+0.75%
Rani Therapeutics Holdings Inc stock is traded at $1.34, with a volume of 3.33M.
It is down -8.84% in the last 24 hours and down -36.79% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$1.47
Open:
$1.48
24h Volume:
3.33M
Relative Volume:
0.19
Market Cap:
$130.72M
Revenue:
$1.20M
Net Income/Loss:
$-52.41M
P/E Ratio:
-1.4725
EPS:
-0.91
Net Cash Flow:
$-31.25M
1W Performance:
-15.72%
1M Performance:
-36.79%
6M Performance:
+139.07%
1Y Performance:
-22.99%
1-Day Range:
$1.34
$1.53
1-Week Range:
$1.34
$1.64
52-Week Range:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.34 | 143.40M | 1.20M | -52.41M | -31.25M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3%Here's Why - MarketBeat
Hedge Fund Bets: Will Rani Therapeutics Holdings Inc. stock outperform tech sector in 2025Quarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - moha.gov.vn
RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal - ts2.tech
Block Trades: Can Rani Therapeutics Holdings Inc. stock beat market expectations this quarterTrade Signal Summary & Weekly Momentum Picks - BỘ NỘI VỤ
Rani Therapeutics to Participate in the Evercore Healthcare Conference - The Manila Times
Why Is Rani Therapeutics’ Stock Skyrocketing Pre-Market Today? - MSN
What drives Rani Therapeutics Holdings Inc stock pricePrice-to-Earnings Ratio Insights & Minimal Investment Portfolio Growth - earlytimes.in
Will Rani Therapeutics Holdings Inc. stock gain from government policiesMarket Movement Recap & Consistent Profit Trading Strategies - newser.com
Technical analysis overview for Rani Therapeutics Holdings Inc. stockJuly 2025 Selloffs & Reliable Trade Execution Plans - newser.com
Is Rani Therapeutics Holdings Inc. stock trading at a premium valuationEarnings Overview Report & Low Drawdown Trading Techniques - newser.com
RANI Stock Today (Nov 19, 2025): Rani Therapeutics slips to $1.75 as traders weigh October’s Chugai deal and year‑end catalysts - ts2.tech
How Rani Therapeutics Holdings Inc. stock compares to market leadersQuarterly Portfolio Review & Consistent Growth Equity Picks - newser.com
Institutional scanner results for Rani Therapeutics Holdings Inc.Earnings Summary Report & Daily Momentum Trading Reports - newser.com
How high can Rani Therapeutics Holdings Inc. stock goLong Setup & Consistent Income Trade Ideas - newser.com
Short interest data insights for Rani Therapeutics Holdings Inc.July 2025 Market Mood & Weekly Momentum Picks - newser.com
How Rani Therapeutics Holdings Inc. stock benefits from global expansionVolume Spike & Weekly Watchlist for Hot Stocks - newser.com
Vasudev Jaiprakash Bailey Net Worth (2025) - GuruFocus
Will Rani Therapeutics Holdings Inc. bounce back from current supportStock Surge & AI Forecasted Entry/Exit Points - newser.com
How to integrate Rani Therapeutics Holdings Inc. into portfolio analysis toolsJuly 2025 Drop Watch & Low Drawdown Investment Strategies - newser.com
Rani Therapeutics Holdings (RANI) Price Target Decreased by 11.90% to 9.44 - MSN
Is Rani Therapeutics Holdings Inc. stock a buy for dividend growthJuly 2025 Retail & Advanced Technical Signal Analysis - newser.com
Is Rani Therapeutics Holdings Inc. stock supported by innovation pipeline2025 Key Lessons & Breakout Confirmation Alerts - newser.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Can Rani Therapeutics Holdings Inc. stock maintain growth trajectoryGap Up & Safe Entry Trade Reports - Fundação Cultural do Pará
Investors Purchase High Volume of Put Options on Rani Therapeutics (NASDAQ:RANI) - MarketBeat
Will Rani Therapeutics Holdings Inc. stock attract more institutional investorsJuly 2025 Reactions & Momentum Based Trading Ideas - newser.com
MSN Money - MSN
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rani Therapeutics Holdings Inc Stock (RANI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):